指南与共识肝肾功能剂量调整药物不良反应与药物警戒

慢性肾脏病患者肾脏剂量调整的实践现状与指南依从性:系统综述与荟萃分析

Current practice and guideline adherence in renal dose adjustment for patients with chronic kidney disease: A systematic review and meta-analysis.
指南 / 共识 · Br J Clin Pharmacol · 2026-08-12

处方/医嘱层面的合并指南依从率为0.48(95%CI 0.42-0.55),患者层面为0.7(95%CI 0.57-0.83),提示依从性欠佳且存在安全隐患。

要点

  • 成人晚期CKD肾脏剂量调整的处方/医嘱层面指南依从率仅约48%。
  • 不依从肾脏剂量调整与不良药物事件及医疗资源使用增加相关。

核心结论

  • 成人晚期CKD患者对肾脏剂量调整推荐的依从性存在差异且可能欠佳,合并估计提示潜在安全缺口。
  • 不依从肾脏剂量推荐与不良临床结局及医疗资源使用增加相关。

研究设计与样本

  • 系统综述与荟萃分析,遵循PRISMA 2020并经PROSPERO注册(CRD42025620883)。

主要发现

  • 处方对肾脏剂量指南的依从率范围为33%至87.7%。
  • 处方/医嘱层面合并指南依从率(n=16)为0.48(95%CI 0.42-0.55;I²约98%)。
  • 患者层面合并指南依从率(n=7)较高,为0.7(95%CI 0.57-0.83;I²约99.9%)。
  • 观察性研究质量中至高等,两项干预性研究因混杂因素存在中等偏倚风险。

临床怎么用

  • 临床药师应关注晚期CKD患者处方中的肾脏剂量调整,识别依从性差距并开展用药审核。
  • 针对不依从高发环节,可设计干预策略以提升剂量调整实践和用药安全。

局限性

  • 纳入研究间存在显著异质性(I²接近98%-99.9%),限制了对合并估计的解释。
  • 两项干预性研究因混杂因素存在中等偏倚风险。
  • 需要高质量研究为改善处方实践和用药安全提供依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To quantify prescribing adherence to renal dosing recommendations in adults with chronic kidney disease (CKD; Stage 3 and above) and to evaluate the clinical consequences of non-adherence. METHODS: This systematic review and meta-analysis was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD42025620883). Eight electronic databases were searched from inception to 31 December 2025. Quantitative studies assessing renal dose adjustment practices in adults with advanced CKD were included in the review. Two reviewers independently performed study selection, data extraction and quality assessment. Random-effects meta-analyses (REML) were used to pool adherence proportions at prescription/order and patient levels. RESULTS: Thirty studies were included in the review. The observational studies were of moderate to high quality, while the two interventional studies had moderate risk of bias due to confounding. Prescribing adherence to renal dosing guidelines ranged from 33% to 87.7%. Pooled prescription/order-level guideline adherence (n = 16) was 0.48 (95% CI 0.42-0.55; I2 ≈ 98%). Conversely, the pooled patient-level guideline adherence (n = 7) was higher at 0.7 (95% CI 0.57-0.83; I2 ≈ 99.9%). The study results suggest that the prevalence of prescribing non-adherence to renal dosing guidelines was high and may be associated with various adverse drug events. CONCLUSIONS: The available evidence suggests that adherence to renal dosing recommendations in adults with advanced CKD is variable and may be suboptimal. The pooled estimate suggests a potential safety gap, although substantial heterogeneity limits interpretation. Furthermore, non-adherence to renal dosing recommendations was associated with adverse clinical consequences and increased healthcare utilization. High-quality studies are needed to inform effective strategies aimed at improving prescribing practices and medication safety.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. ElGeed H, Tehemar A, Gasimelseed M, et al. Current practice and guideline adherence in renal dose adjustment for patients with chronic kidney disease: A systematic review and meta-analysis. Br J Clin Pharmacol. 2026. PMID: 42590882. doi:10.1002/bcp.70731

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。